This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down
Working together for patients with MASH

Novo Nordisk is excited to be involved in the 2024 EASL Congress. A key focus this year is expanding our commitment in areas of high unmet need, in MASH, formerly known as NASH.

MASH is largely a “silent” disease, where up to 90% of people with MASH may be undiagnosed.1

The new name MASH (metabolic dysfunction-associated steatohepatitis) recognises the metabolic basis of this liver disease.2

We look forward to working together to address the underlying threat of MASH.

Working together for patients with MASH

Novo Nordisk is excited to be involved in the 2024 EASL Congress. A key focus this year is expanding our commitment in areas of high unmet need, in MASH, formerly known as NASH.

MASH is largely a “silent” disease, where up to 90% of people with MASH may be undiagnosed.1

The new name MASH (metabolic dysfunction-associated steatohepatitis) recognises the metabolic basis of this liver disease.2

We look forward to working together to address the underlying threat of MASH.

At the 2024 EASL Congress, Novo Nordisk highlights the journey of people diagnosed with MASH (metabolic dysfunction-associated steatohepatitis), and the emotional impact it has from the onset of symptoms, through screening, diagnosis and management of MASH.

 

Learn more about the underlying threat of MASH.
mash at easl
mash at easl

At the 2024 EASL Congress, Novo Nordisk highlights the journey of people diagnosed with MASH (metabolic dysfunction-associated steatohepatitis), and the emotional impact it has from the onset of symptoms, through screening, diagnosis and management of MASH.

 

Learn more about the underlying threat of MASH.

Each year the international liver congress EASL gathers more than 7,000 international healthcare professionals, hepatologists, gastroenterologists and other specialists.

The EASL meeting offers an opportunity to explore cutting-edge research in liver disease, connect with peers, and amplify voices for collective advancement. The EASL Congress 2024 will take place from 5-8 June 2024 in Milan, Italy and online.

EASL Milan 2024 offers a diverse scientific programme focused on shaping the future of liver disease management. Encompassing eight distinct hepatology tracks and catering to professionals at every career stage, this diverse program encourages interdisciplinary approaches to liver diseases and patient care.

The EASL Congress 2024 is hosted by the European Association for the Study of the Liver (EASL). Established in 1966, EASL is committed to advancing liver research, hepatology education, and to further communication between European professionals with an interest in liver diseases.

1.

Schattenberg JM, Lazarus JV, Newsome PN, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int 2021;41(6):1227-42.

2.

Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542–1556.

3.

Yanai H, Adachi H, Hakoshima M, et al. Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int J Mol Sci. 2023;24:15473.

4.

Dulai PS, Singh S, Patel J, et al. Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Hepatology 2017; 65(5):1557–1565.

5.

Marengo A, Jouness RI, Bugianesi E. Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. Clin Liver Dis. 2016;20(2):313–24.

6.

Estes C, Razavi H, Loomba R, et al. Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease. Hepatology, 2018;67(1):123–133.

7.

Loomba R, Adams LA. The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH. Hepatology. 2019;70(6):1885–1888.

8.

Ekstedt M, Hagström H, Nasr P, et al. Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up. Hepatology 2015;61:1547–1554.